<DOC>
	<DOCNO>NCT00590044</DOCNO>
	<brief_summary>Diabetic ketoacidosis ( DKA ) serious emergency patient diabetes . With estimate 100,000 admission per year United States , DKA also lead cause death child type 1 diabetes , account significant proportion admission adult patient type 1 type 2 diabetes . The mainstay treatment DKA involve continuous intravenous ( IV ) infusion regular insulin frequent subcutaneous ( SC ) injection regular rapid-acting insulin analog . Multiple study report successful protocol insulin administration acute management DKA , fail address transition phase IV SC maintenance insulin regimen . The American Diabetes Association ( ADA ) position statement recommend use split-mixed insulin combination regular intermediate-acting insulin ( NPH ) . This regimen , however , associate high rate hyperglycemia shortly discontinuation IV insulin risk hypoglycemia hospital stay . Recently , long-acting `` basal '' insulin glargine ( Lantus® , Sanofi Aventis Pharmaceuticals ) show facilitate glycemic control low rate hypoglycemic event intermediate-acting insulin subject type 1 type 2 diabetes . This study aim ) determine effect give dose glargine insulin shortly start intravenous insulin infusion glycemic control , time resolve DKA , rate hypoglycemia patient DKA , ii ) compare safety efficacy basal/bolus ( glargine/glulisine ) insulin versus standard split-mixed insulin regimen NPH regular insulin resolution DKA . The hypothesis basal ( lantus® ) insulin compare NPH insulin shortly start insulin infusion improve inpatient glycemic control patient DKA . This investigator initiate research conduct Grady Memorial Hospital , Atlanta University Minnesota , MN . Dr Umpierrez design study serve principal investigator . A total 40 patient recruit site .</brief_summary>
	<brief_title>Basal Insulin Management Patients With Diabetic Ketoacidosis ( DKA )</brief_title>
	<detailed_description />
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>All patient admit Grady Memorial Hospital meet diagnosis criterion DKA willing participate study protocol consider candidate inclusion study . Diagnostic Criteria DKA : Blood glucose &gt; 250 mg/dL , arterial venous pH &lt; 7.3 , serum bicarbonate &lt; 18 mEq/L , moderate severe ketonemia ( acetoacetate ≥ 1:4 βhydroxybutyrate &gt; 3 mmol ) . Hemodynamic instability ( MAP &lt; 50 patient require pressor ) Significant identifiable medical surgical illness , include limited : acute myocardial infarction , congestive heart failure ; respiratory failure require mechanical ventilation ; acute chronic renal insufficiency ( serum creatinine &gt; 3.0 mg/dl ) ; end stage liver failure , cirrhosis . Patients dementia persistent alter mental status would prevent collection consent form reliable information . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Diabetic ketoacidosis</keyword>
	<keyword>insulin therapy</keyword>
	<keyword>DKA</keyword>
</DOC>